WHITEHOUSE STATION, N.J. November 26, 2013 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets. NOXAFIL delayed-release tablets are a new formulation with a loading dose of 300 mg (three 100 mg delayed-release tablets) twice […]
LISBON, Portugal, Nov. 26, 2013 /PRNewswire/ — Leading oncology centers have reported on advances in stereotactic radiosurgery (SRS) and stereotactic ablative radiotherapy (SABR) treatments at the first Varian Edge™ Radiosurgery Symposium, held at the Champalimaud Centre for the Unknown in Lisbon, Portugal. Experts from leading centers of excellence around the world presented details of the latest in advanced treatment […]
More than 700 CyberKnife® and TomoTherapy® Systems Have Treated More Than Half a Million Patients Worldwide SUNNYVALE, Calif., November 25, 2013 – Accuray Incorporated (Nasdaq: ARAY) announced today continued momentum in global adoption of its CyberKnife® and TomoTherapy® Systems. Accuray has expanded its installed base to more than 700 systems worldwide which have been used to treat more than […]
Learning and Innovation Center to address radiation therapy training needs STOCKHOLM, November 25 – Today, Chinese government officials, key Elekta radiotherapy customers in China and members of Elekta’s senior management inaugurated Elekta’s Learning and Innovation Center (LINC) in Beijing. The three-story, 1,800sq m (19,375sq ft) education and training facility is equipped with Elekta radiation therapy […]
TrueBeam 2.0 System Installed as The Clatterbridge Cancer Centre Treats 100th Lung Cancer Patient with Varian Radiosurgery Equipment Liverpool, UK, November 25th 2013 – Varian Medical Systems (NYSE: VAR) has installed the latest version of its advanced TrueBeam™ radiotherapy and radiosurgery system at The Clatterbridge Cancer Centre near Liverpool. The TrueBeam system 2.0 is the infrastructure that […]
PITTSBURGH, Nov. 25, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that its partner Biocon has received approval for a Mylan-Biocon trastuzumab product from the Drug Controller General of India. This is the first regulatory approval for a Mylan-Biocon developed biosimilar product. The product is a biosimilar to Roche’s Herceptin®, indicated for the treatment […]
LAVAL, Quebec, Nov. 25, 2013 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that Dr. Ari Kellen has been named to Valeant’s Executive Management Team and will assume the role of Executive Vice President/Company Group Chairman, effective January 1, 2014. Dr. Ari Kellen was a senior partner in McKinsey & […]
NEW YORK & BUDAPEST, Hungary– November 21, 2013 — (BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) and Gedeon Richter Plc. announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for cariprazine, an atypical antipsychotic for the treatment of schizophrenia and for the acute treatment of manic or […]
RICHMOND, Calif., Nov. 20, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that seven abstracts have been accepted for presentation at the 55TH annual meeting of the American Society of Hematology (ASH), which will be heldDecember 7-10, 2013, in New Orleans, LA. “ASH provides an outstanding forum to highlight our advancing pre-clinical IND-candidate programs,” said Edward Lanphier, Sangamo’s president and CEO. “In particular, […]
STOCKHOLM, November 19 – Yonsei University Health System (YUHS) has reinforced its commitment to Elekta’s radiation therapy systems with the recent order of four additional high-end Elekta linear accelerators. The four linear accelerators, representing an order value of approximately USD 10 million, were booked in the second quarter of fiscal year 2013/14. “These systems provide […]